

## Review Article

# Schiff Bases: A Versatile Pharmacophore

Anu Kajal, Suman Bala, Sunil Kamboj, Neha Sharma, and Vipin Saini

M. M. College of Pharmacy, Maharishi Markandeshwar University, Mullana, Ambala, Haryana 133207, India

Correspondence should be addressed to Suman Bala; sumankmj7@gmail.com

Received 3 March 2013; Revised 19 June 2013; Accepted 28 June 2013

Academic Editor: Adel A. Ismail

Copyright © 2013 Anu Kajal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Schiff bases are condensation products of primary amines with carbonyl compounds gaining importance day by day in present scenario. Schiff bases are the compounds carrying imine or azomethine ( $-C=N-$ ) functional group and are found to be a versatile pharmacophore for design and development of various bioactive lead compounds. Schiff bases exhibit useful biological activities such as anti-inflammatory, analgesic, antimicrobial, anticonvulsant, antitubercular, anticancer, antioxidant, anthelmintic, antiglycation, and antidepressant activities. Schiff bases are also used as catalysts, pigments and dyes, intermediates in organic synthesis, polymer stabilizers, and corrosion inhibitors. The present review summarizes information on the diverse biological activities and also highlights the recently synthesized numerous Schiff bases as potential bioactive core.


## 1. Introduction

Schiff bases are the compounds carrying imine or azomethine ( $-C=N-$ ) functional group. These are the condensation products of primary amines with carbonyl compounds and were first reported by Hugo Schiff [1–3]. Schiff bases form an important class of the most widely used organic compounds and have a wide variety of applications in many fields including analytical, biological, and inorganic chemistry. Schiff bases have gained importance in medicinal and pharmaceutical fields due to a broad spectrum of biological activities like anti-inflammatory [4–7], analgesic [5–8], antimicrobial [9, 10], anticonvulsant [11], antitubercular [12], anticancer [13, 14], antioxidant [15], anthelmintic [16], and so forth. The nitrogen atom of azomethine may be involved in the formation of a hydrogen bond with the active centers of cell constituents and interferes in normal cell processes [17, 18]. Apart from biological activities, Schiff bases are also used as catalysts, intermediates in organic synthesis, dyes, pigments, polymer stabilizers [3], and corrosion inhibitors [19]. Studies enlightened that metal complexes show greater biological activity than free organic compounds [20]. Augmentation of biological activity was reported by implementation of transition metals into Schiff bases [21]. Schiff bases played an influencing role in development of coordination chemistry and were involved as key point in the development of

inorganic biochemistry and optical materials [22]. Schiff bases have been utilized as synthons in the preparation of a number of industrial and biologically active compounds like formazans, 4-thiazolidinines, benzoxazines, and so forth, via ring closure, cycloaddition, and replacement reactions [23]. Schiff base derivatives in various processes promoted the researchers for designing of novel heterocyclic/aryl Schiff bases for development of new environmental-friendly technology [24].


## 2. Biological Activities

**2.1. Antimicrobial Activity.** A series of some novel 5-substituted Schiff and Mannich bases of isatin derivatives, that is, 7-(4-((3-(4-(substituted benzylideneamino) phenylimino)-5-fluoro-2-oxindolin-1-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, **1(a–l)**, (Figure 1) were synthesized and characterized for *in vitro* antibacterial activity. Antimicrobial activity of synthesized compounds was assessed by minimum inhibitory concentration (MIC) in comparison with standard antimicrobial drugs, that is, ciprofloxacin and ketoconazole. Compound **1c** was reported to be more active than both of the standard drugs against tested microorganisms which proves the significance of substituted electron-donating groups in improving the antimicrobial activity [25].



<b>1</b>	Ar	<b>1</b>	Ar
<b>a</b>	-C <sub>6</sub> H <sub>5</sub>	<b>g</b>	-4CH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>
<b>b</b>	-4Cl-C <sub>6</sub> H <sub>4</sub>	<b>h</b>	-3,4,5(OCH <sub>3</sub> ) <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>
<b>c</b>	-4OH-C <sub>6</sub> H <sub>4</sub>	<b>i</b>	-4OH, 5-OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>
<b>d</b>	-4OCH <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	<b>j</b>	-5NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>
<b>e</b>	-4NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	<b>k</b>	-4N(CH <sub>3</sub> ) <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>
<b>f</b>	-6OH-C <sub>6</sub> H <sub>4</sub>	<b>l</b>	-CH=HC-C <sub>6</sub> H <sub>4</sub>

FIGURE 1



<b>2</b>	R	<b>2</b>	R
<b>a</b>	2-NO <sub>2</sub>	<b>g</b>	4-OCH <sub>3</sub>
<b>b</b>	3-NO <sub>2</sub>	<b>h</b>	3,4,5-(OCH <sub>3</sub> ) <sub>3</sub>
<b>c</b>	2-OH	<b>i</b>	2-OH, 4-OCH <sub>3</sub>
<b>d</b>	4-OH	<b>j</b>	4-N(CH <sub>3</sub> ) <sub>2</sub>
<b>e</b>	2-Cl	<b>k</b>	2-OH, 4-N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>
<b>f</b>	4-Cl		

FIGURE 2

A novel series of Schiff bases, that is, 6-bromo-2-[2-(2,6-dichlorophenyl)amino]benzyl-3-(substituted benzylideneamino)-quinazolin-4(3H)-one, **2(a-k)**, (Figure 2) has been synthesized and subjected to antimicrobial activity [26].

Evaluation was carried out for the *in vitro* antimicrobial activity by cup plate method. For this, *S. aureus*, *P. aeruginosa*, *B. subtilis*, and *C. albicans* were employed. Penicillin G and amphotericin B were taken as standard drugs. Results revealed that all compounds have moderate to poor antifungal activity and good antibacterial activity [26].

A novel series of pyrazole-based Schiff bases, **3(a-j)**, (Figure 3) 4-[(3-substituted-1H-pyrazol-3-yl)methyleneamino]-5-substituted-4H-1,2,4-triazole-3-thiols, was synthesized and screened for antibacterial activity against the microbial strains of *S. aureus*, *P. aeruginosa*, *B. subtilis*, and *E. coli*. From the results, compound **3f** was found to be equally as active as standard drug ceftriaxone against *P. aeruginosa*, *B. subtilis*, and *E. coli* and most active against *S. aureus* [27].


Synthesis of new open (**4-6**) (Figures 4-6) and macrocyclic (**7**) (Figure 7) Schiff bases has been done and evaluated for the antimicrobial activity. Open Schiff bases were synthesized by the condensation of salicylaldehyde and *o*-vanillin with 4,4'-diaminodiphenylmethane, 4,4'-diamino diphenyl sulphide, and diethyl ester of terephthalic acid, respectively.

Macrocyclic Schiff bases were reported as the condensation product of 1,6-bis(2-formylphenyl)hexane with

thiocarbohydrazone. In order to test the biological activity of the synthesized compounds, four microorganisms (*K. pneumoniae*, *E. coli*, *S. aureus*, and *S. typhimurium*) were employed. All the synthesized compounds were found to be moderate to strongly active [28].

A few novel solid complexes, **8**, (Figure 8) of La(III), Ce(III), Pr(III), Nd(III), Sm(III), and Gd(III) with Schiff base, that is, **9**, (Figure 9) 4-hydroxy-3-(1-{2-(2-hydroxybenzylidene)-amino-phenylimino}-ethyl)-6-methyl-pyran-2-ones, were synthesized and screened for the antibacterial activity against *S. aureus*, *E. coli*, and *Bacillus* species and antifungal activity against *A. niger*, *Trichoderma*, and *F. oxysporum*. Results revealed that the complexes were biologically active and have exhibited enhanced antimicrobial activity than the free ligand (Schiff base) [29].

Some novel Schiff bases, macrocyclic tetradentate nitrogen donor (N<sub>4</sub>) 6,7,14,15-tetrahydroxy-1,4,9,12-tetraazacyclohexadecane-5,8,13,16-tetrone ligand-based metal complexes, **11**, (Figure 11) from **10**, (Figure 10) were synthesized and screened for the *in vitro* antifungal activity and toxicity studies. Minimum inhibitory concentration (MIC) along with ergosterol composition assay against *C. albicans* (ATCC 10261), *C. glabrata* (ATCC 90030), and *C. tropicalis* (ATCC 750) was performed. The antimicrobial results indicated that all the synthesized compounds were found to be active against all fungal strains. It was observed that Ni(II) complex and



<b>3</b>	R	R <sup>1</sup>	<b>3</b>	R	R <sup>1</sup>
<b>a</b>	-C <sub>2</sub> H <sub>5</sub>	H	<b>f</b>	H	H
<b>b</b>	-C <sub>2</sub> H <sub>5</sub>	4-OCH <sub>3</sub>	<b>g</b>	H	4-OCH <sub>3</sub>
<b>c</b>	-C <sub>2</sub> H <sub>5</sub>	4-F	<b>h</b>	H	4-F
<b>d</b>	-C <sub>2</sub> H <sub>5</sub>	4-Cl	<b>i</b>	H	4-Cl
<b>e</b>	-C <sub>2</sub> H <sub>5</sub>	2,4-Cl <sub>2</sub>	<b>j</b>	-C <sub>3</sub> H <sub>7</sub>	4-F

FIGURE 3




FIGURE 4




FIGURE 7





FIGURE 5



M = La(III), Ce(III), Pr(III), Nd(III), and Sm(III)

FIGURE 8




FIGURE 6

Co(II) complex drastically reduced ergosterol content of cell membrane followed by the Cu(II) complex and the ligand itself [30].

**2.2. Antidyslipidemic Activity.** A series of novel keto-enamine Schiff bases, **12(a-h)**, (Figure 12) derived from 8-hydroxyquinoline was synthesized and subjected for *in vitro* antioxidant, *in vivo* antidyslipidemic, and postheparin lipolytic activity.




FIGURE 9




FIGURE 10

Compound **12d**, which was formed from nucleophilic substitutions of 7-methyl aminomethylene-8-oxo-7,8-dihydroquinoline-5-carbaldehyde with *p*-toluidine, was found to be the most potent antidyslipidemic agent [31].

A novel series of keto-enamine Schiff bases, **13(a-h)**, (Figure 13) derived from benzocoumarin was synthesized from 7-hydroxy-4-methyl-2-oxo-2H-benzo [H] chromene-8,10-dicarbaldehyde.

The compounds were evaluated *in vitro* for their antioxidant and *in vivo* for their antidyslipidemic activity. Triton WR-1339 was employed to induce hyperlipidemia. The results revealed that the compounds **13a**, **13e**, and **13i** displayed significant lowering of total cholesterol, phospholipids, and triglycerides in the plasma. Gemfibrozil was used as a standard to compare the results [32].

**2.3. Anthelmintic Activity.** A series of new Schiff bases, **14(a-e)** (Figure 14) containing 4(3H)-quinazoline ring system was synthesized by the condensation reaction of 3-amino-2-methyl-4(3H)quinazolinone (AMQ) with different substituted aromatic aldehydes in methanol. The compounds were also evaluated for their anthelmintic, antioxidant, and antimicrobial activities. Indian adult earthworms (*P. posthuma*) were employed for the anthelmintic activity.

Piperazine citrate was used as a reference standard while DMSO as a control for comparison. Results revealed that all the synthesized compounds were moderately active except compound **14c** which was found to be the most potent anthelmintic agent due to presence of chloro group. Chloro group may improve the conductance of worm muscle membrane that causes reduction in hyperpolarization and excitability which leads to flaccid paralysis that results in expulsion of worm by peristaltic movement [33].


A series of twelve new N-substituted-2-hydroxyacetophenonimine derivatives, **15(a-l)** (Figure 15) was synthesized by conventional as well as microwave method. Synthesized compounds were evaluated for their antinemic activity by calculating  $LC_{50}$  values of different synthesized imines against  $J_{2s}$  of *M. incognita*. Carbofuran was employed as a standard.

Although all the compounds possessed activity against *M. incognita*, N-hexyl-2-hydroxyacetophenonimine (**15j**), N-hexyl-2-hydroxypropiophenonimine (**15k**), and N-propyl-2-hydroxypropiophenonimine (**15l**) were found to possess significant activity with  $LC_{50}$  values of 99.60, 74.46, 109.53, and  $mgL^{-1}$ , respectively, as compared to other imines. The above observations enlightened that bioactivity increased with increase in chain length up to 6 carbon atoms whereas further increase in chain length decreased the activity [34].

**2.4. Antitubercular Activity.** A novel series of forty-four, **17(i-xxxiv)**, (Figure 17) Schiff bases of isonicotinic acid hydrazide (INH) was synthesized by structural modification of **16** (Figure 16) in which hydrazine unit was chemically blocked at  $N^2$  position by deactivating acetylation by N-arylaminoacetyl transferase (NATs) enzyme. The deactivation phenomenon seems to be associated with rise of resistance. Synthesized Schiff bases were blocked toward the enzymatic deactivation process. The results revealed that compound **17(xv)** was found to be the most potent antitubercular agent with MIC 0.05  $\mu g/mL$  and  $\log P$  4.04 [35].

A series of Schiff bases of indoline-2,3-dione derivatives and nalidixic acid carbohydrazides, **18(a-n)** (Figure 18) was synthesized and screened for antitubercular activity against four *Mycobacterium* strains (*M. xenopi*, *M. cheleneo*, *M. intracellulare*, and *M. smegmatis*) using isonicotinic acid hydrazide as a standard drug. Agar dilution method was opted for screening the activity. From the results, compound **18f** was found to be the most potent antitubercular agent with MIC 0.625  $\mu g/mL$  which is 20 times higher than the MIC of standard drug (12.5  $\mu g/mL$ ) [36].

Synthesis of six D-mannitol-derived Schiff bases, **19(a-f)** (Figure 19) 1,6-dideoxy-1,6-bis-[(E)-arylmethylidene]amino-D-mannitol was carried out and synthesized compounds were evaluated for their *in vitro* antitubercular activity against *M. tuberculosis* H<sub>37</sub>Rv by employing microplate Alamar Blue assay (MABA). Compounds **19e**, **19d**, and **19f** have shown significant inhibitory activity when compared with standard drug ethambutol (first-line drug) due to presence of nitro group while chlorine-containing compounds (**19a**, **19b**, and **19c**) have shown resistance. MIC values for **19e**, **19d**, and **19f** were found to be 12.5, 25.0, and 25  $\mu g/mL$ , respectively [37].



M = Cu(II), Co(II), and Ni(II)

FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15





FIGURE 16



17	R <sub>1</sub>	R <sub>2</sub>
xv	H	4-(CH=NNHCOC <sub>5</sub> H <sub>4</sub> N)C <sub>6</sub> H <sub>4</sub>

FIGURE 17




FIGURE 18






FIGURE 19



<b>20</b>	R	<b>20</b>	R
<b>a</b>	2-OHC <sub>6</sub> H <sub>5</sub>	<b>g</b>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>
<b>b</b>	4-OHC <sub>6</sub> H <sub>5</sub>	<b>h</b>	4-OH, 3-OHCH <sub>3</sub> C <sub>6</sub> H <sub>3</sub>
<b>c</b>	4-ClC <sub>6</sub> H <sub>4</sub>	<b>i</b>	2-C <sub>4</sub> H <sub>3</sub> O
<b>d</b>	4-NO <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	<b>j</b>	4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>
<b>e</b>	2-NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub>	<b>k</b>	4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub>
<b>f</b>	4-FC <sub>6</sub> H <sub>4</sub>		

FIGURE 20



<b>21</b>	R <sub>1</sub>	R <sub>2</sub>	<b>21</b>	R <sub>1</sub>	R <sub>2</sub>
<b>a</b>	H	4-OH	<b>g</b>	CH <sub>3</sub>	4-Cl
<b>b</b>	H	3,4(OCH <sub>3</sub> ) <sub>2</sub>	<b>h</b>	CH <sub>3</sub>	4-NO <sub>2</sub>
<b>c</b>	H	3-NO <sub>2</sub>	<b>i</b>	CH <sub>3</sub>	4-OCH <sub>3</sub>
<b>d</b>	CH <sub>3</sub>	2-OH	<b>j</b>	CH <sub>3</sub>	2,4-(Cl) <sub>2</sub>
<b>e</b>	CH <sub>3</sub>	4-OH	<b>k</b>	CH <sub>3</sub>	2-OH, OCH <sub>3</sub>
<b>f</b>	CH <sub>3</sub>	4-CH <sub>3</sub>	<b>l</b>	CH <sub>3</sub>	2-NO <sub>2</sub>

FIGURE 21

**2.5. Antidepressant Activity.** Schiff bases of isonicotinoyl hydrazone, *N'*-[(1*Z*)-(substituted aromatic)methylidene]pyridine-4-carbohydrazides, **20(a-k)** (Figure 20) were synthesized by green route of microwave synthesis and sonication. Synthesized compounds were evaluated for *in vivo* antidepressant and nootropic activities. The results revealed that the test compounds substituted with nitro, halogen, and dimethoxy groups exhibited significant antidepressant and nootropic activities. *N'*-[(1*Z*)-(2,5 dimethoxyphenyl)methylidene]pyridine-4-carbohydrazide was found to exhibit the highest antidepressant activity [38].

**2.6. Anticonvulsant Activity.** A series of Schiff bases of phthalimide, 4-(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)-*N'*-(substituted phenyl)methylene/ethylidene benzohydrazide, **21(a-i)** (Figure 21) was synthesized and evaluated for anticonvulsant and neurotoxic activities [39].

From the results, it was concluded that all the compounds were found to be active and less toxic than phenytoin which was employed as a standard drug. Compound **21l** substituted with nitro group at ortho position of distal aryl ring was reported as the most potent anticonvulsant agent [39].

Synthesis of a series of 3,3'[[6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diyl]dinitrolo]bis-(substituted-1,3-dihydro-2*H*-indol-2-one), **22** (Figure 22) of lamotrigine with isatin and substituted isatin was carried out and screened for the anticonvulsant activity. MES (maximal electroshock seizure)

test method was opted to carry out the anticonvulsant activity by incorporation of lamotrigine and phenobarbitone sodium as standard drugs. Results revealed that the synthesized compounds possessed better anticonvulsant activity than the standard lamotrigine [40].

Some novel 3-aryl-4(3*H*)-quinazolinones-2-carboxaldehydes and their corresponding Schiff bases, **23** (Figure 23) and thiosemicarbazone derivatives, have been synthesized. Compounds showed anticonvulsant, analgesic, and cytotoxic potential due to thiosemicarbazone side chain at position ending with a free amino group and fluorine atom [41].

**2.7. Anti-Inflammatory, Analgesic, and Nonulcerogenic Activities.** A novel series of Schiff bases containing sydnone that is, 3-[1-(4-isobutylphenyl)ethyl]-4-(3-substituted-4-sydnonylidene) amino 5-mercapto-1,2,4-triazoles, **24(a-c)**, (Figure 24) was synthesized and screened for their anti-inflammatory and analgesic activities. Results revealed that compound **24c**, 3-[1-(4-isobutylphenyl)ethyl]-4-[3-(*p*-anisyl)-4-sydnonylidene] amino 5-mercapto-1,2,4-triazole, exhibited good anti-inflammatory and analgesic activities as compared to **24a** and **24b** which indicated that presence of electron-releasing group in sydnone has resulted in better anti-inflammatory and analgesic activities [42].

Synthesis of novel Schiff base analogues of 4-amino-1,5-dimethyl-2-phenylpyrazol-3-one, **25(a-m)**, (Figure 25) was carried out. Synthesized compounds were screened for




FIGURE 22




FIGURE 23




FIGURE 24




FIGURE 25




FIGURE 26




FIGURE 27

the anti-inflammatory and antioxidant activities. Compound **25f** was found to be the most potent anti-inflammatory agent and antioxidant. The anti-inflammatory activity of **25f** was evaluated in terms of its potential of nitric oxide (NO) production inhibition in LPS-pretreated RAW 264.7 cells using the Griess method.

Lipopolysaccharide (LPS), an endotoxin which is derived from the cell wall of Gram-negative bacteria, can induce multiple signaling pathways to stimulate the production of inflammatory modulators involving NO, PGE<sub>2</sub>, TNF- $\alpha$ , and interleukins. The results indicated that 50  $\mu$ g/mL of **25f** inhibited the LPS-stimulated COX-2 mRNA levels [43].

A series of S-substituted phenacyl 1,3,4-oxadiazoles and Schiff bases **26(a-k)** (Figure 26) derived from 2-[(2,6-dichloroanilino) phenyl] acetic acid (diclofenac acid) was synthesized and screened for the analgesic, anti-inflammatory, and nonulcerogenic activities. Acetic-acid-induced writhing test and carrageenan-induced rat paw edema method were employed for analgesic and anti-inflammatory activities, respectively. From the studies it was concluded that synthesized compounds were devoid of gastrointestinal toxicities. Among all the synthesized compounds, N-(4-bromobenzylidene)-[2-(2,6-dichloroaniline)benzyl carbazide] **26k** was found to be the most potent anti-inflammatory agent. The analgesic effect of **26k** (68.66%) was found to be better than that of diclofenac sodium (64.65%) [44].

**2.8. Antitumor Activity.** A novel series of fluoroquinolone C-3 heterocycles (IV), that is, *s*-triazole Schiff **27(a-k)** (Figure 27) and mannich bases derivatives of ofloxacin was

synthesized and evaluated for *in vitro* antitumor activity against a murine leukemia cell line (L1210), a human leukocytoma cell line (HL60), and a Chinese hamster ovary cell line (CHO) using the MTT assay. From the observed results it was concluded that a free phenol group containing compounds **27c**, **27g**, and **27h** exhibited more potent activity than the other test compounds [45].

A series of thirteen quinolin-2(1H)-one-derived Schiff bases **28(a-m)** (Figure 28) and their Cu(II) **29(a-m)** (Figure 28) complexes was synthesized. Selected compounds were screened for their *in vitro* anticancer and antifungal activities. Human hepatic carcinoma cell line, Hep-G<sub>2</sub> was employed for screening of the anticancer potential. Cisplatin was used as a standard drug for the comparison. Screened compounds were found to be active antifungal agents and compound (7E)-7-(3-ethoxy-2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one was reported as a potent cytotoxic agent which enlightened the good potential of Cu(II) complexes of Schiff base ligands as therapeutic agents [46].

A series of three Schiff bases 4-([3-(4-substituted phenyl)-1H-pyrazol-4-yl] methylene)amino-5-[(substituted phenoxy)methyl]-1,2,4-triazole-3-thiol, **30(a-c)** (Figure 29) was evaluated for their *in vivo* antitumor activity against Ehrlich-ascites-carcinoma-(EAC-) bearing Swiss albino mice. Schiff bases were used in two different doses, that is, 50 mg/kg and 100 mg/kg of the body weight of mice. Mean survival time (MST) and percentage increase in lifespan (% ILS), that is, total number of days an animal survived from the day of tumor inoculation were calculated. Body weights




FIGURE 28




FIGURE 29

of all animals were measured on days 0, 3, 5, 7, 10, 12, and 14 [47].

The results revealed that cisplatin (3.5 mg/kg, i.p. single dose) significantly enhanced MST of EAC-infected mice. Among the three Schiff bases 4-([3-(4-fluorophenyl)-1H-pyrazol-4-yl]methylene)amino)-5-[(2-methylphenoxy)methyl]-1,2,4-triazole-3-thiol, **30c**, at the dose of 100 mg/kg body weight was found to enhance the mean survival time of tumor-bearing mice. MST and deviated hematological parameters of infected mice were found to be normal after treatment with **30c** [47].

**2.9. Antioxidant Activity.** A series of substituted-*N'*-[(1E)-substituted phenylmethylidene]benzohydrazide analogs, **31(a-n)** (Figure 30) was synthesized and evaluated for their *in vitro* antioxidant, anti-inflammatory, and antimicrobial activities. The antioxidant activity of all the synthesized compounds was evaluated by the phosphomolybdenum method. Compounds **31c**, **31d**, and **31f** were reported to show good antioxidant activity due to presence of 4-nitro, 4-methyl, and 3-nitro groups, respectively, whereas **31a** having 4-hydroxy group did not possess such activity. From the results, it can be concluded that substitutions like nitro and alkyl lead to enhancement in antioxidant activity through one-electron transfer mechanism [48].

A new Schiff base ligand *N*-(2-hydroxyacetophenone)-3-oxapentane-1,5-diamine (HL), **32**, and its Ni complex,

[Ni<sub>2</sub>(L)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>], **33**, were synthesized and evaluated for antioxidation and DNA-binding properties. The complex showed inhibitory activity and the suppression ratio of OH radical increases with increase in the concentration of the complex. Mannitol and vitamin C were employed as the standard antioxidants for comparison. According to the results the 50% inhibitory concentration (IC<sub>50</sub>) value of **33** was found to be 8.1 ± 0.078 μM whereas IC<sub>50</sub> for mannitol was 9.6 μM and **32** was devoid of antioxidant activity. Both **32** and **33** bind to DNA in intercalation mode but the binding strength of **33** was found to be better than **32** [49].

**2.10. Antiviral Activity.** A series of 3-(benzylideneamino)-2-phenylquinazoline-4(3H)-one, **34(a-l)** (Figure 31) was synthesized and evaluated for their cytotoxicity and antiviral activity. Compounds having 2-hydroxy substitution showed better antiviral activity [50].

A series of thiazolines and azetidinones was synthesized by reaction of Schiff bases, **35(a-i)**, (Figure 32) (intermediate reaction) with thioglycolic acid and chloral acetyl chloride, respectively. Schiff bases were evaluated for antibacterial and antiviral (against HIV-1) potential. All the compounds were found to be good HIV-1 inhibitors except **35f** and **35g** [51].

**2.11. Antihypertensive Activity.** Schiff bases of 2-phenyl-3-(amino substituted arylidene)quinazoline-4-(3H)-ones, **36(a-b)** (Figure 33) were synthesized and evaluated for




FIGURE 30




FIGURE 31




FIGURE 32

antihyperlipidemic activity. Hyperlipidemia was induced in rats by atherogenic diet. After 45 days, levels of serum total cholesterol (TC) and LDL cholesterol were recorded to be  $231.6 \pm 1.435$  mg/dL and  $164.53 \pm 1.26$  mg/dL which were comparatively higher than normal rat serum TC ( $71.36 \pm 1.195$  mg/dL) and LDL-C ( $100.66 \pm 0.88$  mg/dL) levels whereas serum HDL-C level was found to be lower ( $19.012 \pm 0.66$  mg/dL) as compared to the normal level ( $50.66 \pm 0.88$  mg/dL).

Results revealed that **36a** reduced TC and LDL-C levels to  $172.41 \pm 41$  mg/dL and  $91.10 \pm 0.97$  mg/dL and raised serum HDL-C level to  $60.07 \pm 0.67$  mg/dL whereas **36b** reduced serum TC and LDL-C levels to  $93.63 \pm 1.292$  and  $81.35 \pm 0.81$  mg/dL and raised serum HDL-C level to  $59.40 \pm 0.45$  mg/dL at the dose of 200 mg/kg, p.o., once daily [52].

**2.12. Antidiabetic and Antiglycation Activities.** A series of oxovanadium complexes with mixed ligands, a bidentate NN ligand, **37**, and a tetradentate ONO-donor Schiff base ligand, **38** (Figure 34) was synthesized and evaluated for protein tyrosine phosphate (PTP) inhibition. PTP1B has been identified as key enzyme related to insulin resistance. Thus the inhibition of PTP1B has emerged out as an important approach to enhance insulin sensitivity. The kinetic analysis results revealed that oxovanadium complexes displayed potent reversible competitive inhibition PTP1B with  $IC_{50}$  values in low nanomolar range [53].

A series of twenty-seven bis-Schiff base of isatin, **39(i-xxvii)** (Figure 35) was synthesized and evaluated for their *in vitro* antiglycation activity. Compounds **39(xx)** and **39(xxi)** substituted with nitro groups at *para* and *ortho* positions,




FIGURE 33





FIGURE 34




FIGURE 35

respectively, were found to be the most potent antiglycation agents with  $IC_{50}$  ( $257.61 \pm 5.63 \mu M$ ) and  $243.95 \pm 4.59 \mu M$  better than  $IC_{50}$  ( $294.46 \pm 1.50 \mu M$ ) of rutin which was employed as standard. The 3,4-dihydroxy analog **39(vii)** was found as the third most potent antiglycation agent with  $IC_{50}$  ( $291.14 \pm 2.53 \mu M$ ) [54].

### 3. Conclusion

Schiff bases are one of the most important chemical classes of compounds having a common integral feature of a variety of medicinal agents. This review reflects the contribution of Schiff bases to the design and development of novel lead having potential biological activities with fewer side effects. This bioactive core has maintained the interest of researchers in gaining the most suggestive and conclusive access in the






field of various Schiff bases of medicinal importance for last decades. The present paper is an attempt to review all the biological activities reported for Schiff bases in the current literature with an update of recent research findings.

### References

- [1] Z. Cimerman, S. Miljanić, and N. Galić, "Schiff bases derived from aminopyridines as spectrofluorimetric analytical reagents," *Croatica Chemica Acta*, vol. 73, no. 1, pp. 81–95, 2000.
- [2] H. Schiff, "Mittheilungen aus dem Universitätslaboratorium in Pisa: eine neue reihe organischer Basen," *Justus Liebigs Annalen der Chemie*, vol. 131, no. 1, pp. 118–119, 1864.
- [3] D. N. Dhar and C. L. Taploo, "Schiff bases and their applications," *Journal of Scientific and Industrial Research*, vol. 41, no. 8, pp. 501–506, 1982.

- [4] B. S. Sathe, E. Jaychandran, V. A. Jagtap, and G. M. Sreenivasa, "Synthesis characterization and anti-inflammatory evaluation of new fluorobenzothiazole schiff's bases," *International Journal of Pharmaceutical Research and Development*, vol. 3, no. 3, pp. 164–169, 2011.
- [5] S. M. Sondhi, N. Singh, A. Kumar, O. Lozach, and L. Meijer, "Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases," *Bioorganic and Medicinal Chemistry*, vol. 14, no. 11, pp. 3758–3765, 2006.
- [6] A. Pandey, D. Dewangan, S. Verma, A. Mishra, and R. D. Dubey, "Synthesis of schiff bases of 2-amino-5-aryl-1,3,4-thiadiazole and its analgesic, anti-inflammatory, anti-bacterial and anti-tubercular activity," *International Journal of ChemTech Research*, vol. 3, no. 1, pp. 178–184, 2011.
- [7] C. Chandramouli, M. R. Shivanand, T. B. Nayanbhai, B. Bheemachari, and R. H. Udupi, "Synthesis and biological screening of certain new triazole schiff bases and their derivatives bearing substituted benzothiazole moiety," *Journal of Chemical and Pharmaceutical Research*, vol. 4, no. 2, pp. 1151–1159, 2012.
- [8] R. P. Chinnasamy, R. Sundararajan, and S. Govindaraj, "Synthesis, characterization, and analgesic activity of novel schiff base of isatin derivatives," *Journal of Advanced Pharmaceutical Technology and Research*, vol. 1, no. 3, pp. 342–347, 2010.
- [9] K. Mounika, B. Anupama, J. Pragathi, and C. Gyanakumari, "Synthesis, characterization and biological activity of a Schiff base derived from 3-ethoxy salicylaldehyde and 2-amino benzoic acid and its transition metal complexes," *Journal of Scientific Research*, vol. 2, no. 3, pp. 513–524, 2010.
- [10] P. Venkatesh, "Synthesis, characterization and antimicrobial activity of various schiff bases complexes of Zn(II) and Cu(II) ions," *Asian Journal of Pharmaceutical and Health Sciences*, vol. 1, no. 1, pp. 8–11, 2011.
- [11] A. K. Chaubey and S. N. Pandeya, "Synthesis & anticonvulsant activity (Chemo Shock) of Schiff and Mannich bases of Isatin derivatives with 2-Amino pyridine (mechanism of action)," *International Journal of PharmTech Research*, vol. 4, no. 4, pp. 590–598, 2012.
- [12] T. Aboul-Fadl, F. A. Mohammed, and E. A. Hassan, "Synthesis, antitubercular activity and pharmacokinetic studies of some Schiff bases derived from 1-alkylisatin and isonicotinic acid hydrazide (INH)," *Archives of Pharmacal Research*, vol. 26, no. 10, pp. 778–784, 2003.
- [13] R. Miri, N. Razzaghi-asl, and M. K. Mohammadi, "QM study and conformational analysis of an isatin Schiff base as a potential cytotoxic agent," *Journal of Molecular Modeling*, vol. 19, no. 2, pp. 727–735, 2013.
- [14] S. M. M. Ali, M. Abul Kalam Azad, M. Jesmin et al., "In vivo anticancer activity of Vanillin semicarbazone," *Asian Pacific Journal of Tropical Biomedicine*, vol. 2, no. 6, pp. 438–442, 2012.
- [15] D. Wei, N. Li, G. Lu, and K. Yao, "Synthesis, catalytic and biological activity of novel dinuclear copper complex with Schiff base," *Science in China B*, vol. 49, no. 3, pp. 225–229, 2006.
- [16] P. G. Avaji, C. H. Vinod Kumar, S. A. Patil, K. N. Shivananda, and C. Nagaraju, "Synthesis, spectral characterization, in-vitro microbiological evaluation and cytotoxic activities of novel macrocyclic bis hydrazone," *European Journal of Medicinal Chemistry*, vol. 44, no. 9, pp. 3552–3559, 2009.
- [17] K. N. Venugopala and B. S. Jayashree, "Synthesis of carboxamides of 2'-amino-4'-(6-bromo-3-coumarinyl) thiazole as analgesic and antiinflammatory agents," *Indian Journal of Heterocyclic Chemistry*, vol. 12, no. 4, pp. 307–310, 2003.
- [18] K. Vashi and H. B. Naik, "Synthesis of novel Schiff base and azetidinone derivatives and their antibacterial activity," *European Journal of Chemistry*, vol. 1, pp. 272–276, 2004.
- [19] S. Li, S. Chen, S. Lei, H. Ma, R. Yu, and D. Liu, "Investigation on some Schiff bases as HCl corrosion inhibitors for copper," *Corrosion Science*, vol. 41, no. 7, pp. 1273–1287, 1999.
- [20] Z. H. Chohan, M. Praveen, and A. Ghaffar, "Structural and biological behaviour of Co(II), Cu(II) and Ni(II) metal complexes of some amino acid derived Schiff-bases," *Metal-Based Drugs*, vol. 4, no. 5, pp. 267–272, 1997.
- [21] S. Ershad, L. Sagathforoush, G. Karim-Nezhad, and S. Kangari, "Electrochemical behavior of N<sub>2</sub>SO Schiff-base Co(II) complexes in non-aqueous media at the surface of solid electrodes," *International Journal of Electrochemical Science*, vol. 4, no. 6, pp. 846–854, 2009.
- [22] F. Tisato, F. Refosco, and G. Bandoli, "Structural survey of technetium complexes," *Coordination Chemistry Reviews*, vol. 135–136, pp. 325–397, 1994.
- [23] A. Jarrahpour, D. Khalili, E. De Clercq, C. Salmi, and J. M. Brunel, "Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives," *Molecules*, vol. 12, no. 8, pp. 1720–1730, 2007.
- [24] A. Bhattacharya, V. C. Purohit, and F. Rinaldi, "Environmentally friendly solvent-free processes: novel dual catalyst system in Henry reaction," *Organic Process Research and Development*, vol. 7, no. 3, pp. 254–258, 2003.
- [25] C. R. Prakash and S. Raja, "Synthesis, characterization and in vitro antimicrobial activity of some novel 5-substituted Schiff and Mannich base of isatin derivatives," *Journal of Saudi Chemical Society*, 2011.
- [26] N. B. Patel and J. C. Patel, "Synthesis and antimicrobial activity of Schiff bases and 2-azetidinones derived from quinazolin-4(3H)-one," *Arabian Journal of Chemistry*, vol. 4, no. 4, pp. 403–411, 2011.
- [27] S. Malladi, A. M. Isloor, S. Isloor, and D. S. Akhila, "Synthesis, characterization and antibacterial activity of some new pyrazole based Schiff bases," *Arabian Journal of Chemistry*, vol. 6, no. 3, pp. 335–340, 2013.
- [28] H. H. Essa, F. Kandil, and A. Falah, "Synthesis and identification of schiff bases and biological activity new study," *Iraqi Journal of Science*, vol. 53, no. 2, pp. 230–240, 2012.
- [29] V. A. Shelke, S. M. Jadhav, V. R. Patharkar, S. G. Shankarwar, A. S. Munde, and T. K. Chondhekar, "Synthesis, spectroscopic characterization and thermal studies of some rare earth metal complexes of unsymmetrical tetradentate Schiff base ligand," *Arabian Journal of Chemistry*, vol. 5, pp. 501–507, 2012.
- [30] R. A. Sheikh, M. Y. Wani, S. Shreaz, and A. A. Hashmi, "Synthesis, characterization and biological screening of some Schiff base macrocyclic ligand based transition metal complexes as antifungal agents," *Arabian Journal of Chemistry*, 2011.
- [31] K. V. Sashidhara, A. Kumar, G. Bhatia, M. M. Khan, A. K. Khanna, and J. K. Saxena, "Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases," *European Journal of Medicinal Chemistry*, vol. 44, no. 4, pp. 1813–1818, 2009.
- [32] K. V. Sashidhara, J. N. Rosaiah, G. Bhatia, and J. K. Saxena, "Novel keto-enamine Schiffs bases from 7-hydroxy-4-methyl-2-oxo-2H-benzo[h] chromene-8,10-dicarbaldehyde as potential antidyslipidemic and antioxidant agents," *European Journal of Medicinal Chemistry*, vol. 43, no. 11, pp. 2592–2596, 2008.

- [33] H. D. Revanasiddappa, K. S. Prasad, L. S. Kumar, and B. Jayalakshmi, "Synthesis and biological activity of new schiff bases containing 4(3H)-quinazolinone ring system," *International Journal of ChemTech Research*, vol. 2, no. 2, pp. 1344–1349, 2010.
- [34] A. Kundu, N. A. Shakil, D. B. Saxena, P. Pankaj, J. Kumar, and S. Walia, "Microwave assisted solvent-free synthesis and biological activities of novel imines (Schiff bases)," *Journal of Environmental Science and Health B*, vol. 44, no. 5, pp. 428–434, 2009.
- [35] M. J. Hearn, M. H. Cynamon, M. F. Chen et al., "Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid," *European Journal of Medicinal Chemistry*, vol. 44, no. 10, pp. 4169–4178, 2009.
- [36] T. Aboul-Fadl, F. A. S. Bin-Jubair, and O. Aboul-Wafa, "Schiff bases of indoline-2,3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building," *European Journal of Medicinal Chemistry*, vol. 45, no. 10, pp. 4578–4586, 2010.
- [37] M. D. L. Ferreira, T. R. A. Vasconcelos, E. M. de Carvalho et al., "Synthesis and antitubercular activity of novel Schiff bases derived from d-mannitol," *Carbohydrate Research*, vol. 344, no. 15, pp. 2042–2047, 2009.
- [38] A. B. Thomas, R. K. Nanda, L. P. Kothapalli, and S. C. Hamane, "Synthesis and biological evaluation of Schiff's bases and 2-azetidiones of isonicotinyldiazide as potential antidepressant and nootropic agents," *Arabian Journal of Chemistry*, 2011.
- [39] M. A. Bhat and M. A. Al-Omar, "Synthesis, characterization and in vivo anticonvulsant and neurotoxicity screening of Schiff bases of phthalimide," *Acta Polonica Pharmaceutica*, vol. 68, no. 3, pp. 375–380, 2011.
- [40] A. A. Kulkarni, S. B. Wankhede, N. D. Dhawale, P. B. Yadav, V. V. Deore, and I. D. Gonjari, "Synthesis, characterization and biological behavior of some Schiff's and Mannich base derivatives of anticonvulsant drugs," *Arabian Journal of Chemistry*, <http://dx.doi.org/10.1016/j.arabjc.2012.07.020>.
- [41] M. M. Aly, Y. A. Mohamed, K. A. M. El-Bayouki, W. M. Basyouni, and S. Y. Abbas, "Synthesis of some new 4(3H)-quinazolinone-2-carboxaldehyde thiosemicarbazones and their metal complexes and a study on their anticonvulsant, analgesic, cytotoxic and antimicrobial activities e Part-1," *European Journal of Medicinal Chemistry*, vol. 45, no. 8, pp. 3365–3373, 2010.
- [42] Nithinchandra, B. Kalluraya, S. Aamir, and A. R. Shabaraya, "Regioselective reaction: synthesis, characterization and pharmacological activity of some new Mannich and Schiff bases containing sydnone," *European Journal of Medicinal Chemistry*, vol. 54, pp. 597–604, 2012.
- [43] M. S. Alam, J. Choi, and D. Lee, "Synthesis of novel Schiff base analogues of 4-amino-1, 5-dimethyl-2- phenylpyrazol-3-one and their evaluation for antioxidant and anti-inflammatory activity," *Bioorganic & Medicinal Chemistry*, vol. 20, pp. 4103–4108, 2012.
- [44] S. V. Bhandari, K. G. Bothara, M. K. Raut, A. A. Patil, A. P. Sarkate, and V. J. Mokale, "Design, synthesis and evaluation of antiinflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives," *Bioorganic and Medicinal Chemistry*, vol. 16, no. 4, pp. 1822–1831, 2008.
- [45] G. Hu, G. Wang, N. Duan et al., "Design, synthesis and antitumor activities of fluoroquinolone C-3 heterocycles(IV): s-triazole Schiff-Mannich bases derived from ofloxacin," *Acta Pharmaceutica Sinica B*, vol. 2, no. 3, pp. 312–317, 2012.
- [46] B. S. Creaven, B. Duff, D. A. Egan et al., "Anticancer and antifungal activity of copper(II) complexes of quinolin-2(1H)-one-derived Schiff bases," *Inorganica Chimica Acta*, vol. 363, no. 14, pp. 4048–4058, 2010.
- [47] S. Dhanya, A. M. Isloor, P. Shetty, P. G. Nayak, and K. S. R. Pai, "In vivo anticancer and histopathology studies of Schiff bases on Ehrlich ascitic carcinoma cells," *Arabian Journal of Chemistry*, 2010.
- [48] S. Bala, G. Uppal, S. Kamboj, V. Saini, and D. N. Prasad, "Design, characterization, computational studies, and pharmacological evaluation of substituted-N'-[(1E) substitutedphenylmethylidene]benzohydrazide analogs," *Medicinal Chemistry Research*, vol. 21, no. 11, pp. 1–13, 2012.
- [49] H. Wu, F. Jia, F. Kou, B. Liu, J. Yuan, and Y. Bai, "A Schiff base ligand N-(2-hydroxyacetophenone)-3-oxapentane-1, 5-diamine and its nickel(II) complex: Synthesis, crystal structure,antioxidation, and DNA-binding properties," *Transition Metal Chemistry*, vol. 36, no. 8, pp. 847–853, 2011.
- [50] K. S. Kumar, S. Ganguly, R. Veerasamy, and E. De Clercq, "Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazolinone-4(3H)-ones," *European Journal of Medicinal Chemistry*, vol. 45, no. 11, pp. 5474–5479, 2010.
- [51] R. N. Patel, P. V. Patel, K. R. Desai, P. Y. Purohit, K. S. Nimavat, and K. B. Vyas, "Synthesis of new heterocyclic schiff base, thiazolidinone and azetidione compounds and their antibacterial activity and anti-hiv activities," *Heterocyclic Letters*, vol. 2, no. 1, pp. 99–105, 2012.
- [52] S. Ganguli, M. Firdous, T. S. Maity, R. K. Bera, and M. Panigrahi, "The study of antihyperlipidemic activities of schiff bases of 4(3H) quinazolinone derivatives in rats," *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 4, no. 2, pp. 175–178, 2012.
- [53] C. Yuan, L. Lu, X. Gao et al., "Ternary oxovanadium(IV) complexes of ONO-donor Schiff base and polypyridyl derivatives as protein tyrosine phosphatase inhibitors: synthesis, characterization, and biological activities," *Journal of Biological Inorganic Chemistry*, vol. 14, no. 6, pp. 841–851, 2009.
- [54] K. M. Khan, M. Khan, M. Ali et al., "Synthesis of bis-Schiff bases of isatins and their antiglycation activity," *Bioorganic and Medicinal Chemistry*, vol. 17, no. 22, pp. 7795–7801, 2009.



**Hindawi**

Submit your manuscripts at  
<http://www.hindawi.com>

